(UroToday.com) The Society of Urologic Oncology (SUO) annual winter meeting included a kidney cancer session and a presentation by Dr. Ari Hakimi discussing clinical and genomic updates in sarcomatoid renal cell carcinoma (RCC). Dr. Hakimi started by noting that sarcomatoid dedifferentiation is seen in ~5% of all kidney cancer, and ~20% of patients with metastatic disease. This is associated with an aggressive de-differentiated state with a very poor prognosis in which, historically, surgery and systemic therapies were ineffective.